Fetal Nuchal Translucency Measurement for Detection of Fetal Anomalies

First trimester sonographic examination has become a very important method for detection of fetal anomalies since FASTER trial. According to FASTER trial, the nuchal translucency measurement could be combined with two first trimester maternal serum analyses, free (3-hCG, pregnancy associated plasma protein A (PAPP-A). This combined screening test is a very sensitive method for detection of Down syndrome. First trimester screening for chromosomal abnormalities provides advantages over second trimester screening. When the results are negative, first trimester screening may reduce a maternal anxiety at early gestational age. When the results are positive the screening test allows the patient to take first trimester prenatal diagnosis. If the fetus is found to be affected earlier in the pregnancy it offers women greater privacy if the patients elect to terminate the pregnancy. Together with nuchal translucency measurement, nasal bone(NB), ductus venosus (DV) blood flow, tricuspid regurgitation (TR), and frontᄋmaxillary facial angle are useful tests with optimal detection rates. We review the guidelines and standardized method of nuchal translucency measurement of first trimester sonographic examination and its significance.